Objective. Women with antiphospholipid antibodies (aPL) are at risk for pregnancy complications associated with poor placentation and placental inflammation. Although these antibodies are heterogeneous, some antib 2 -glycoprotein I (anti-b 2 GPI) antibodies can activate Toll-like receptor 4 (TLR-4) and NLRP3 in human firsttrimester trophoblasts. The objective of this study was to determine the role of negative regulators of TLR and inflammasome function in aPL-induced trophoblast inflammation.
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Objective. Women with antiphospholipid antibodies (aPL) are at risk for pregnancy complications associated with poor placentation and placental inflammation. Although these antibodies are heterogeneous, some antib 2 -glycoprotein I (anti-b 2 GPI) antibodies can activate Toll-like receptor 4 (TLR-4) and NLRP3 in human firsttrimester trophoblasts. The objective of this study was to determine the role of negative regulators of TLR and inflammasome function in aPL-induced trophoblast inflammation.
Methods. Human trophoblasts were not treated or were treated with anti-b 2 GPI aPL or control IgG in the presence or absence of the common TAM (TYRO3, AXL, and Mer tyrosine kinase [MERTK] ) receptor ligand growth arrest-specific protein 6 (GAS6) or the autophagyinducer rapamycin. The expression and function of the TAM receptor pathway and autophagy were measured by quantitative reverse transcription-polymerase chain reaction (qRT-PCR), Western blotting, and enzyme-linked immunosorbent assay (ELISA). Antiphospholipid antibody-induced trophoblast inflammation was measured by qRT-PCR, activity assays, and ELISA.
Results. Anti-b 2 GPI aPL inhibited trophoblast TAM receptor function by reducing cellular expression of the receptor tyrosine kinases AXL and MERTK and the ligand GAS6. The addition of GAS6 blocked the effects of aPL on the TLR-4-mediated interleukin-8 (IL-8) response. However, the NLRP3 inflammasomemediated IL-1b response was not affected by GAS6, suggesting that another regulatory pathway was involved. Indeed, anti-b 2 GPI aPL inhibited basal trophoblast autophagy, and reversing this with rapamycin inhibited aPL-induced inflammasome function and IL1b secretion.
Conclusion. Basal TAM receptor function and autophagy may serve to inhibit trophoblast TLR and inflammasome function, respectively. Impairment of TAM receptor signaling and autophagy by anti-b 2 GPI aPL may allow subsequent TLR and inflammasome activity, leading to a robust inflammatory response.
Women with antiphospholipid antibodies (aPL) are at high risk for recurrent pregnancy loss and late gestational pregnancy complications, such as preeclampsia (1) . Placental inflammation is a hallmark of adverse pregnancy outcomes such as preeclampsia, including those complicated by aPL (2, 3) . Antiphospholipid antibodies recognizing b 2 -glycoprotein I (b 2 GPI) preferentially bind the placental trophoblast and subsequently alter trophoblast function (4, 5) . Our group previously demonstrated that aPL recognizing b 2 GPI trigger human first-trimester trophoblasts to produce elevated levels of proinflammatory cytokines/chemokines via activation of Toll-like receptor 4 (TLR-4) (6) and independently of TLR-4, inhibit spontaneous trophoblast migration and modulate trophoblast angiogenic factor secretion (7, 8) . Further investigation of this TLR-4-mediated inflammatory response revealed that anti-b 2 GPI aPL increased induction of endogenous uric acid in the trophoblast, which in turn activated the NLRP3 inflammasome to induce interleukin-1b (IL-1b) processing and secretion (9) . In parallel, anti-b 2 GPI aPL induced trophoblast expression of microRNA-146a-3p (miR-146a-3p) through activation of TLR-4, which in turn activated the RNA sensor TLR-8 to drive IL-8 secretion (10) .
Despite the ability of some aPL to induce a robust TLR-4 and NLRP3 inflammasome-mediated inflammatory response, human first-trimester trophoblast cells do not generate a classic inflammatory response to physiologic doses of the natural TLR-4 ligand, bacterial lipopolysaccharide (LPS) (11) (12) (13) (14) . Thus, in human firsttrimester trophoblasts, TLR-4 function and subsequent inflammasome activation may be tightly regulated, and aPL might override this braking mechanism.
One way in which TLR function can be inhibited is via activation of TAM receptor tyrosine kinases, a novel family of negative regulators (15, 16) . Three TAM receptors, TYRO3, AXL, and Mer tyrosine kinase (MERTK), are activated by 2 endogenous ligands: growth arrestspecific protein 6 (GAS6) and protein S1 (PROS1). GAS6 binds and activates all 3 TAM receptors, while PROS1 activates TYRO3 and MERTK (15, 16) . Upon ligand binding, TAM receptors trigger STAT-1 phosphorylation, inducing expression of suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3, which inhibits TLR signaling (15, 16) . While autophagy is a regulatory process that facilitates the degradation and recycling of cytoplasmic components via lysosomes (17) , autophagy is also a negative regulator of inflammasome activity and subsequent IL-1b production (18, 19) . Furthermore, in normal pregnancy, extravillous trophoblasts express high levels of basal autophagy, which is necessary for their invasion and vascular remodeling (20) . The aim of this study was to determine the role of negative regulators of TLR and inflammasome function in anti-b 2 GPI aPL-induced trophoblast inflammation, by investigating the TAM receptor pathway and autophagy.
MATERIALS AND METHODS
Reagents. Recombinant GAS6 was purchased from R&D Systems. The autophagy inducer rapamycin and the autophagy inhibitor bafilomycin were obtained from InvivoGen. The ADAM-17 inhibitor tumor necrosis factor a processing inhibitor 0 (TAPI-0) was purchased from Sigma-Aldrich.
Trophoblast cell lines. The human first-trimester extravillous trophoblast telomerase-transformed cell line Sw.71 (21) was used in these studies. The human first-trimester extravillous trophoblast cell line HTR-8 was also used and was a kind gift from Dr. Charles Graham (Queens University, Kingston, Ontario, Canada) (22) .
Isolation of primary trophoblasts from first-trimester placentas. Placentas from first-trimester pregnancies (7-12 weeks' gestation) were obtained from elective terminations of normal pregnancies performed at Yale New Haven Hospital. The use of patient samples was approved by the Yale University Human Research Protection Program. Trophoblast isolation was performed as previously described (10) .
Antiphospholipid antibodies. Unless specified otherwise, we used the aPL IIC5, which is a mouse IgG1 anti-human b 2 GPI monoclonal antibody (mAb). For some experiments, the aPL ID2, which also is an IgG mouse anti-human b 2 GPI mAb, was used. These aPL have been previously characterized. Similar to patient-derived polyclonal aPL, IIC5 and ID2 bind b 2 GPI when immobilized on a negatively charged surface such as phospholipids, cardiolipin, phosphatidylserine, or irradiated polystyrene and thus behave as both anticardiolipin and antib 2 GPI antibodies (23) . IIC5 and ID2 react specifically with an epitope within domain V of b 2 GPI (24). Furthermore, both IIC5 and ID2 have pronounced lupus anticoagulant activity, and thus both antibodies are "triple positive" aPL (25) . IIC5 and ID2 are appropriate models for human aPL, because they share similar epitopes; IIC5 and ID2 can block human polyclonal aPL binding to b 2 GPI (26) . Moreover, IIC5 and ID2 bind to human first-trimester extravillous trophoblast cells (6, 27, 28) and alter their function in a manner similar to patient-derived polyclonal IgG aPL (9) and polyclonal IgG aPL recognizing b 2 GPI (6, 8) . In particular, for this study, both antihuman b 2 GPI mAb and patient-derived aPL up-regulated trophoblast secretion of inflammatory IL-8 and IL-1b (6, 9) . Mouse IgG1 clone 107.3 (BD Biosciences) was used as an isotype control. Trophoblast cells were treated with aPL or the IgG isotype control at 20 lg/ml, as previously described (6) (7) (8) (9) (10) .
RNA isolation and quantitative reverse transcriptionpolymerase chain reaction (qRT-PCR). Trophoblast cell RNA was extracted using TRIzol, as previously described (29) . Expression of miR-146a-3p was measured by qRT-PCR using a TaqMan MicroRNA Assay (Life Technologies) and normalized to the housekeeping gene U6, as previously described (10) . For expression of TYRO3, AXL, MERTK, GAS6, PROS1, SOCS1, SOCS3, IFNA, IFNB, and GAPDH messenger RNA (mRNA), qRT-PCR was performed using a KAPA SYBR FAST qPCR kit (Kapa Biosystems), and PCR amplification was performed using a Bio-Rad CFX Connect Realtime PCR Detection System. Data were analyzed using the DDC t method and plotted as the fold change in microRNA or mRNA expression normalized to the endogenous control/internal reference.
Western blotting. Western blot analysis was performed as previously described (9) . Hsp90 was used as an internal control to validate the amount of protein loaded onto the gels. Images were recorded, and semiquantitative densitometry was performed using a Kodak Gel Logic 100 system and Kodak Molecular Imaging software (Eastman Kodak) and normalized to signals for Hsp90. The following primary antibodies to human proteins were used: TYRO3 (catalog no. MAB859; R&D Systems); AXL (catalog no. AF154; R&D Systems); MERTK (catalog no. AF891; R&D Systems), phosphorylated AXL (catalog no. 9271; Cell Signaling Technology), phosphorylated MERTK (catalog no. ab192649; Abcam), total STAT-1 (catalog no. 9172; Cell Signaling Technology), phosphorylated STAT-1 (catalog no. 7649; Cell A, Quantitative reverse transcription-polymerase chain reaction was used to measure basal TYRO3, AXL, MERTK, GAS6, and PROS1 mRNA levels in the Sw.71 cell line (n = 6), the HTR-8 cell line (n = 3), and primary first-trimester trophoblasts (n = 3). B, After 48 hours of no treatment (NT) or exposure to aPL or control IgG, TYRO3, AXL, MERTK, GAS6, and PROS1 mRNA levels were measured in Sw.71 cells (n = 8). C and D, Sw.71 cells were not treated or were treated with aPL or control IgG. After 72 hours, cell-free supernatants and cellular protein were collected. C, Total AXL (tAXL) and phosphorylated AXL (pAXL) (part i) and total MERTK (tMERTK) and phosphorylated MERTK (pMERTK) (part ii) were measured by Western blotting. Hsp90 served as a loading control. D, Enzyme-linked immunosorbent assays were performed to measure secreted growth arrest-specific protein 6 (GAS6) and cellular GAS6 (parts i and ii, respectively) and secreted protein S1 (PROS1) and cellular PROS1 (n = 4-8) (parts iii and iv). Total AXL and phosphorylated AXL and total MERTK and phosphorylated MERTK levels were determined by densitometry, after normalization to Hsp90 (n = 4-6). Blots are from 1 representative experiment. Bars show the mean AE SEM of pooled independent experiments. * = P < 0.05 versus NT.
Signaling Technology), SOCS-1 (catalog no. 3950; Cell Signaling Technology), SOCS-3 (catalog no. 2923; Cell Signaling Technology), light chain 3B-I (LC3B-I/II) (catalog no. 2775; Cell Signaling Technology), SQSTM1/p62 (catalog no. 5114; Cell Signaling Technology), and Hsp90 (catalog no. H-114; Santa Cruz Biotechnology).
Measurement of cytokines, uric acid, caspase 1, and TAM receptor ligands, and trophoblast migration. Trophoblast culture supernatants and (for some factors) lysates, were analyzed for IL-1b, vascular endothelial growth factor (VEGF), placenta growth factor (PlGF), soluble endoglin, and GAS6 using enzyme-linked immunosorbent assay (ELISA) kits from R&D Systems; for IL-8 using an ELISA kit from Enzo Life Sciences; and for total PROS1 using an ELISA kit from Innovative Research. For the measurement of uric acid, supernatants were analyzed using a QuantiChrom Assay Kit from Bioassay Systems. Caspase 1 activity was measured using a Caspase-Glo 1 Inflammasome Assay (Promega). Trophoblast cell migration was measured using a 2-chamber colorimetric assay (EMD Millipore), as previously described (7, 10) .
Measurement of soluble AXL, soluble MERTK, and GAS6 in patient samples. Plasma was collected as part of the Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus (PROMISSE) study, a multicenter National Institutes of Health-funded prospective observational study of pregnancy in women with aPL, systemic lupus erythematosus (SLE), or both, as well as healthy pregnant controls. Details about this cohort of women, as well as inclusion and exclusion criteria, have been previously reported (9, 10, (30) (31) (32) (33) . The current study involves a subset of aPL-positive pregnant women with SLE or without SLE (n = 38) and healthy pregnant controls (n = 16). We also studied SLE patients without aPL (n = 29). Adverse pregnancy outcomes were defined as the occurrence of ≥1 of the following: 1) otherwise unexplained fetal death, 2) neonatal death prior to hospital discharge and due to complications of prematurity, 3) indicated preterm delivery prior to 37 weeks' gestation because of gestational hypertension, preeclampsia, or placental insufficiency, 4) birth weight less than the fifth percentile and/or delivery before 37 weeks because of intrauterine growth retardation and confirmed by a birth weight less than the 10th percentile. The frequency of adverse pregnancy outcomes in the entire cohort was previously reported (10) . Among individuals who did or did not have SLE and were aPL-positive, 20 had an adverse pregnancy outcome; among patients with SLE who were aPL-negative, 11 had an adverse pregnancy outcome. Plasma collected during the second trimester (18-27 weeks' gestation) was analyzed for soluble AXL, soluble MERTK, and GAS6 using ELISA (R&D Systems).
Statistical analysis. Each treatment experiment was performed at least 3 times. All analyses were performed in duplicate or triplicate. All data are presented as the mean AE SEM of pooled independent experiments. For normally distributed data, significance was determined by either one-way analysis of variance for multiple comparisons or a t-test. For non-normally distributed data, significance was determined using a nonparametric multiple comparison test or Wilcoxon's matched pairs signed rank test. Statistical analyses were performed using GraphPad Prism software. P values less than 0.05 were considered significant.
RESULTS
Inhibition of trophoblast TAM receptor and ligand expression by aPL. As shown in Figure 1A , firsttrimester trophoblast cell lines (Sw.71 and HTR-8) as well as primary human first-trimester trophoblasts expressed basal mRNA levels of the TAM receptors TYRO3, AXL, and MERTK and their ligands, GAS6 and PROS1. After treatment with aPL or an IgG isotype control, trophoblast TYRO3, AXL, MERTK, GAS6, and PROS1 mRNA levels were not significantly different from those in the no treatment (NT) control group (Figure 1B) . However, as shown in Figures 1C and D , aPL treatment did change their protein expression. Under NT and IgG control conditions, trophoblasts expressed high levels of total and phosphorylated AXL and MERTK ( Figure 1C , parts i and ii, respectively). After exposure to aPL, the levels of total and phosphorylated AXL were significantly reduced (mean AE SEM 75.9 AE 9.1% and 49.9 AE 11.7%, respectively), as were the levels of total and phosphorylated MERTK (84.1 AE 4.7% and 76.0 AE 6.2%, respectively) compared to the NT control ( Figure 1C , parts i and ii, respectively). TYRO3 protein expression was undetectable under all conditions (data not shown). As shown in Figure 1D , under NT and IgG control conditions, trophoblasts expressed high levels of secreted and cellular GAS6 and PROS1. After exposure to aPL, secreted (part i) and cellular (part ii) GAS6 levels were significantly reduced (78.6 AE 5.3% and 81.4 AE 3.4%, respectively) compared to the NT control. In contrast, aPL had no significant effect on either secreted or cellular levels of PROS1 compared to controls ( Figure 1D , parts iii and iv, respectively).
Inhibition of trophoblast TAM receptor signaling by aPL. Having demonstrated reduced expression of AXL, MERTK, and GAS6 protein and reduced AXL and MERTK activation in trophoblasts exposed to aPL, we investigated the functional impact of this inhibition by examining the downstream signaling pathway. Under NT and IgG control conditions, trophoblasts expressed high levels of phosphorylated and total STAT-1 and high levels of SOCS-1 and SOCS-3 ( Figure 2A ). After treatment with aPL, the phosphorylated STAT-1:total STAT-1 ratio was significantly inhibited (mean AE SEM 62.4 AE 11.6%) compared to the NT control (Figures 2A and B) . After treatment with aPL, the expression of SOCS-1 and SOCS-3 protein was also significantly inhibited (mean AE SEM 76.4 AE 6.0% and 30.1 AE 5.2%, respectively) compared to the NT control (Figures 2A and C) . This was reflected at the mRNA level. Treatment of trophoblasts with aPL significantly reduced SOCS1 and SOCS3 mRNA levels (mean AE SEM 58.9 AE 11.3% and 30.1 AE 8.3%, respectively) when compared to the NT control ( Figure 2D ). Because type I interferons (IFNs) can also induce SOCS-1/SOCS-3 expression through activation of the IFN-a/b receptor (IFNAR) (34) , the effects of aPL on these factors were examined. As shown in Figure 2D , treatment of trophoblasts with aPL significantly reduced IFNB mRNA levels (78.6 AE 7.0%) compared to the NT control, while control IgG had no significant effect. IFNA mRNA levels were not altered under all conditions (data not shown).
GAS6 reverses aPL-induced miR-146a-3p expression and IL-8 secretion, but not uric acid or IL-1b production. To determine whether attenuation of the TAM receptor signaling pathway by aPL plays a role in regulating the trophoblast TLR-4-mediated inflammatory response (6,9,10), recombinant GAS6 was introduced into the culture. As shown in Figure 3A , TLR-4-mediated aPL-induced IL-8 secretion (part i) and miR-146a-3p expression (part ii) were both inhibited by the presence of recombinant GAS6. Recombinant GAS6 significantly inhibited aPL-induced IL-8 secretion (29.7 AE 9.8%) and miR-146a-3p expression (37.8 AE 9.0%). In contrast, the TLR-4-mediated induction of IL-1b secretion (part iii), uric acid production (part iv), and caspase 1 activation (part v) by aPL was not altered by recombinant GAS6 ( Figure 3A) . As shown in Figure 3B , the aPL-mediated TLR-4-independent regulation of trophoblast VEGF, PlGF, soluble endoglin, and cell migration (7, 8) was not reversed by the presence of recombinant GAS6. However, there were some minimal, yet statistically significant, effects of recombinant GAS6 on trophoblast angiogenic factor production. As shown in Figure 3B , recombinant GAS6 significantly increased aPL-induced VEGF (mean AE SEM 1.1 AE 0.1-fold) (part i), reduced basal PlGF (16.8 AE 10.1%) (part ii), and increased basal and aPL-induced expression of soluble endoglin (1.1 AE 0.1 and 1.2 AE 0.1-fold, respectively) (part iii).
Antiphospholipid antibodies promote trophoblast soluble MERTK release through ADAM-17. We next investigated the mechanism by which aPL inhibit the TAM receptor signaling pathway, allowing for subsequent TLR-4-mediated miR-146a-3p expression and IL-8 secretion. The ectodomain of MERTK is proteolytically cleaved by the metalloproteinase ADAM-17 to generate soluble MERTK (35, 36) , while soluble AXL is released through activation of ADAM-10 (37). To investigate whether aPL treatment promoted the release of soluble AXL and soluble MERTK, which may account for the reduced cellular expression, trophoblasts were treated with or without aPL, and the cell-free culture supernatants were evaluated for the soluble receptors. As shown in Figure 4A , under both NT and IgG control conditions, soluble MERTK was undetectable by Western blotting. However, after exposure to aPL, there was a significant (mean AE SEM 32.8 AE 3.1-fold) increase in soluble MERTK expression. Surprisingly, under NT and IgG control conditions, there was a high amount of detectable soluble AXL, and treatment with aPL significantly reduced this (57.7 AE 13.9%) ( Figure 4A ). To examine the mechanism by which aPL promote trophoblast soluble MERTK release, trophoblasts were treated with aPL in the presence or absence of an ADAM-17 inhibitor. As shown in Figure 4B , treatment of trophoblasts with the ADAM-17 inhibitor TAPI-0 completely and significantly reversed the ability of aPL to reduce cellular MERTK expression.
Elevated levels of circulating soluble AXL in pregnant women with aPL and adverse pregnancy outcomes. We next sought to determine whether our in vitro findings, which model what occurs in the placental Figure 3 . Recombinant growth arrest-specific protein 6 (rGAS6) reverses aPL-induced microRNA-146a-3p (miR-146a-3p) expression and interleukin-8 (IL-8) secretion. Sw.71 or HTR8 cells were not treated or were treated with aPL in the presence of media or rGAS6 (100 ng/ml). Cellular RNA was collected or cell migration was measured after 48 hours (n = 5), and cell-free supernatants were collected after 72 hours (n = 5). A, Toll-like receptor 4 (TLR-4)-mediated IL-8 secretion (part i), fold change (FC) in miR-146a-3p expression (part ii), IL-1b secretion (part iii), uric acid secretion (part iv), and caspase 1 activity (part v) were measured. B, TLR-4-independent regulation of vascular endothelial growth factor (VEGF) secretion (part i) and placenta growth factor (PlGF) secretion (part ii), soluble endoglin (sEndoglin) secretion (part iii), and cell migration (part iv) were measured. Bars show the mean AE SEM. * = P < 0.05 versus NT (media or rGAS6) unless otherwise indicated. RLU = relative luminescence units (see Figure 1 for other definitions). trophoblast at the maternal-fetal interface, were detectable at the systemic level. We analyzed plasma samples that were collected at 18-27 weeks' gestation from aPL-positive pregnant women (with or without SLE) for soluble AXL, soluble MERTK, and GAS6 levels, and compared them to women with or without an adverse pregnancy outcome. As shown in Figure 5A , plasma levels of soluble AXL in aPL-positive women (with or without SLE) who did or did not have an adverse pregnancy outcome were significantly higher compared to the levels in plasma from healthy controls. Moreover, aPL-positive women (with or without SLE) who had an adverse pregnancy outcome had significantly higher levels of soluble AXL compared to aPL-positive women (with or without SLE) without an adverse pregnancy outcome ( Figure 5A ). To determine whether adverse pregnancy outcomes in women with autoimmune disease but without detectable aPL have aberrant expression of soluble AXL, we analyzed plasma from aPL-negative SLE patients with or without adverse pregnancy outcomes. Plasma levels of soluble AXL in aPL-negative SLE patients, either with an adverse pregnancy outcome or without an adverse pregnancy outcome, were not significantly different from those in healthy controls and were significantly lower than the levels in aPL-positive women (with or without SLE) with an adverse pregnancy outcome ( Figure 5A ). There were no significant differences in the plasma levels of soluble MERTK ( Figure 5B ) or GAS6 ( Figure 5C ) between any of the patient groups or controls.
Antiphospholipid antibodies inhibit trophoblast autophagy, leading to inflammasome activation. Despite inhibiting TAM receptor function, recombinant GAS6 did not reverse the effects of aPL on TLR-4-mediated uric acid production, caspase 1 activation, and subsequent IL-1b secretion (9) . Therefore, we examined other regulatory pathways that might be involved in the modulation of this aPL inflammasome-mediated response (9) . Because autophagy is a negative regulator of inflammasome activity (18, 19) and is active under normal conditions in extravillous trophoblasts (20) , we investigated this process. As shown in Figure 6A , under NT and IgG control conditions, trophoblasts expressed the autophagy markers LC3B-I and LC3B-II and sequestosome 1 (p62), a specific autophagy substrate (38) . After treatment with 2 different aPL (IIC5 and ID2), the trophoblast LC3B-II:LC3B-I ratio was significantly reduced compared to NT control (mean AE SEM 43.3 AE 20.1% and 60.3 AE 16.1%, respectively), while levels of p62 were unchanged under all treatment conditions ( Figure 6A ).
The levels of p62 are known to stabilize or accumulate when LC3B-II/LC3B-I-associated autophagy is impaired in the trophoblast and other model systems (20, 38, 39) . To determine whether the observed reduction in autophagy might allow for aPL-mediated inflammasome function, trophoblast cells were treated with aPL in the presence of the autophagy inducer rapamycin. As shown in Figure 6B , although aPLinduced uric acid production was not affected by the presence of rapamycin (part i), aPL-induced caspase 1 activity (part i) and IL-1b secretion (part ii) were significantly inhibited (52.0 AE 2.6% and 77.1 AE 3.6%, respectively). Figure 6C shows that in the absence of aPL, treatment of trophoblasts with the autophagy Figure 5 . Circulating soluble AXL (sAXL) levels are elevated in pregnant women with antiphospholipid antibodies (aPL) and adverse pregnancy outcomes. The levels of soluble AXL (A), soluble Mer tyrosine kinase (sMERTK) (B), and growth arrest-specific protein 6 (GAS6) (C) were measured in plasma from healthy controls who did not have an adverse pregnancy outcome (APO-) (n = 16), aPL-positive women with or without systemic lupus erythematosus (SLE) who did not have an adverse pregnancy outcome (n = 18), aPL-positive women with or without SLE who had an adverse pregnancy outcome (n = 20), aPL-negative women with SLE who did not have an adverse pregnancy outcome (n = 19), and aPL-negative women with SLE who had an adverse pregnancy outcome (n = 11). Symbols represent individual subjects; horizontal lines with bars indicate the mean AE SEM.
inhibitor bafilomycin had no effect on uric acid production (part i). However, when compared to the NT control, bafilomycin significantly increased trophoblast caspase 1 activity (4.8 AE 0.2-fold) (part ii) and IL-1b secretion (181.9 AE 50.8-fold) (part iii).
DISCUSSION
Placental inflammation is a hallmark of pregnancy complications such as preeclampsia and preterm birth (40) , but in many cases the trigger and mechanisms involved are unknown. In obstetric antiphospholipid syndrome, it is well established that pathogenic aPL recognizing b 2 GPI target the placenta, causing pathology that results in pregnancy loss and late gestational complications (5). Although pregnancies complicated by aPL show evidence of inflammation at the maternal-fetal interface (2,3), our understanding of the mechanisms involved is incomplete. In the current study, we report for the first time that aPL override negative regulators of placental trophoblast TLR and inflammasome signaling to induce a robust inflammatory response.
Through the expression of a wide range of innate immune TLRs, nucleotide-binding oligomerization domainlike receptors (NLRs), and inflammasome family members, the trophoblast can generate diverse inflammatory, specialized, and regulatory responses to infectious stimuli (11, 41) . These pathways can also be activated by noninfectious triggers (42) (43) (44) , including aPL (6,9,10). Specifically, aPL recognizing b 2 GPI, upon binding to human firsttrimester extravillous trophoblasts, activate the TLR-4 pathway to induce endogenous secondary signals that in turn activate other innate immune pathways within the cell (6). TLR-4-mediated uric acid production in response Figure 6 . Antiphospholipid antibodies (aPL) inhibit trophoblast autophagy, leading to inflammasome activation. A, Sw.71 cells were not treated (NT) or were treated with aPL or control IgG. After 8 hours, cellular protein was collected. Western blotting was performed to detect light chain 3B-I (LC3B-I), LC3B-II, and p62. Hsp90 served as a loading control. Blots are from 1 representative experiment. The LC3B-II:LC3B-I ratio and levels of p62 were determined by densitometry after normalization to Hsp90 (n = 4). B, Sw.71 cells were not treated or were treated with aPL in the presence of media or rapamycin (500 nM). After 72 hours, supernatants were measured for uric acid (part i), caspase 1 activity (part ii), or interleukin-1b (IL-1b) (part iii) (n = 6-7). C, Sw.71 cells were not treated or were treated with bafilomycin (0.5 lM). After 72 hours, supernatants were measured for uric acid (part i), caspase 1 activity (part ii), or IL-1b (part iii) (n = 6-7). Bars show the mean AE SEM. * = P < 0.05 versus NT control, unless otherwise indicated. RLU = relative luminescence units.
to anti-b 2 GPI antibodies activates the NLRP3 inflammasome, promoting an IL-1b response (9) . At the same time, TLR-4-mediated expression of miR-146a-3p leads to activation of TLR-8, promoting an IL-8 response (10) . Recent studies of endothelial cells have also demonstrated that aPL activation of TLR-4 can lead to the induction of secondary mediators of pathology (45) . It is important to note that both human polyclonal aPL and the well-characterized anti-b 2 GPI mAb used in the current study induced similar trophoblast inflammatory responses, specifically elevated IL-8 and uric acid-mediated IL-1b processing and secretion (6, 9) . However, aPL are highly heterogeneous, and thus our findings may not apply to all aPL.
Despite being able to sense and respond to a number of different TLR and NLR ligands (41, 46) , physiologic doses of the natural TLR-4 agonist, LPS, are not sufficient to induce human first-trimester trophoblasts to generate a classic inflammatory cytokine response (11) (12) (13) (14) . A recent study showed that the type I interferon IFNb serves as a key immunomodulator of LPS-driven TLR-4 activation in the trophoblast (14) , indicating that in these cells, TLR-4 signaling is indeed tightly regulated. Thus, in contrast to immune system cells, the trophoblast innate immune properties may be constitutively limited by negative regulatory mechanisms (16) . The aim of the current study was to investigate how aPL recognizing b 2 GPI, which can directly interact with TLR-4 (45, 47, 48) and activate the TLR-4 pathway (6,9), might overcome such braking mechanisms.
Herein, we report that under basal conditions, human first-trimester trophoblasts constitutively express high levels of the TAM receptors AXL and MERTK and the TAM receptor ligands GAS6 and PROS1, indicating that TLR function in these cells is constitutively suppressed (16) . Indeed, the TAM receptor signaling pathway is highly active in these cells under resting conditions, as evidenced by AXL, MERTK, and STAT-1 phosphorylation and high expression of SOCS-1 and SOCS-3. Although AXL has a greater affinity for GAS6 than does MERTK (49), unlike AXL, MERTK can bind both GAS6 and PROS1 (16) . Thus, because trophoblasts produce both ligands, MERTK might be the dominant functional TAM receptor in resting human first-trimester trophoblasts. After exposure to antib 2 GPI aPL, trophoblast expression of total and phosphorylated AXL and MERTK as well as GAS6 was inhibited, resulting in inactivation of the TAM receptor signaling pathway. This allowed for the TLR-4-mediated miR-146a-3p-TLR-8 arm of the aPL-driven inflammatory pathway (10) to occur, since this could be blocked by recombinant GAS6. In addition to acting as a TAM receptor ligand, GAS6 can modulate AXL and MERTK expression (50, 51) .
Thus, the addition of recombinant GAS6 may serve as both an agonist and receptor modulator in order to reestablish TAM receptor function. As expected, the TLR-4-independent effects of aPL on trophoblast function were not reversed by recombinant GAS6.
One way in which TAM receptor expression and activation can be regulated is through the generation of proteolytically cleaved soluble proteins. Soluble AXL and soluble MERTK are released through activation of the metalloproteinases ADAM-10 and ADAM-17, respectively (35) (36) (37) . In the current study, we show that under basal conditions, trophoblasts constitutively released soluble AXL, but not soluble MERTK. This further supports the notion that MERTK might be the dominant functional TAM receptor in human first-trimester trophoblasts under basal conditions. Treatment of trophoblasts with aPL induced the release of soluble MERTK, while soluble AXL release was reduced. Furthermore, under aPL conditions, ADAM-17 inhibition reversed the reduced cellular expression of MERTK. This suggests that aPL promotes the release of soluble MERTK from the trophoblast cell surface, which may account for the reduced cellular expression. Indeed, in other cell types, LPS can promote soluble MERTK release, resulting in reduced cellular expression (35, 36) . In contrast, the aPL-induced inhibition of cellular AXL expression may account for reduced soluble AXL release. How aPL are able to inhibit AXL protein expression in the trophoblast remains unclear but may involve AXL protein degradation. Soluble AXL and soluble MERTK act as decoy receptors for GAS6 to further prevent cell surface receptor activation. Thus, under aPL conditions, binding of GAS6 by the remaining soluble AXL and the increased level of soluble MERTK may also sequester it from detection and may be responsible, in part, for the aPL-mediated reduction in trophoblast GAS6.
Having demonstrated that aPL differentially regulated trophoblast release of soluble AXL and soluble MERTK, we sought to determine whether this might also be seen clinically at the systemic level. To investigate this, soluble AXL, soluble MERTK, and GAS6 levels were measured in plasma from aPL-negative and aPL-positive women enrolled in the PROMISSE study (9, 10, (30) (31) (32) (33) . Soluble MERTK and GAS6 levels in plasma were not different between the patient groups and controls. However, aPL-positive pregnant women (with or without SLE) had higher levels of circulating soluble AXL compared to controls. Moreover, aPL-positive women with an adverse pregnancy outcome had higher circulating levels of soluble AXL compared to aPL-positive women without an adverse pregnancy outcome. This finding was specific for aPL positivity, because soluble AXL levels in the aPLnegative groups with SLE were not different from those in healthy controls. Although these findings did not reflect our in vitro findings, and thus what might occur locally at the maternal-fetal interface, these clinical data suggest that soluble AXL levels in plasma measured during the second trimester (18-27 weeks' gestation) might correlate with pregnancy outcome, although further investigation is warranted. Prior to this study, circulating soluble AXL, soluble MERTK, and GAS6 levels had been studied in nonpregnant patients with SLE, soluble AXL and soluble MERTK levels have been reported as being higher in SLE patients (52) (53) (54) , while data for GAS6 levels vary (53, 55) . One study also showed that in SLE patients, elevated levels of soluble AXL and soluble MERTK were correlated with aPL positivity (56) . However, our findings constitute the first report of soluble AXL, soluble MERTK, and GAS6 levels in pregnant women with aPL and/or SLE.
Another potential contributor to the disabled TAM receptor pathway in the trophoblast was the observed alterations in IFNb, because type I IFNs (through IFNAR), either alone or in cooperation with TAM receptors, can induce SOCS-1/SOCS-3 (34) . Thus, inhibition of trophoblast IFNb expression by anti-b 2 GPI antibodies might contribute to inactivation of the TAM receptor signaling pathway. The ability of aPL to render IFNb signaling inactive is similar to findings in which trophoblasts were infected with a virus (14) .
Although restoration of TAM receptor signaling by recombinant GAS6 prevented an aPL-mediated IL-8 response in the trophoblast, the TLR-4-mediated uric acid response, and subsequent NLRP3 inflammasome-mediated IL-1b response (9) were not affected. This suggested that additional inhibitory pathways may be involved in regulating the aPL-induced trophoblast inflammatory response. Autophagy is a regulatory process that facilitates the degradation and recycling of cytoplasmic components via lysosomes (17) . Although autophagy is important for cellular homeostasis and cell survival in response to a number of stresses (57) , it can also act as a negative regulator of inflammasome activity and subsequent IL-1b production (18, 19) .
In normal pregnancy, basal autophagy is essential for extravillous trophoblast invasion and vascular remodeling (20) . Moreover, in the setting of preeclampsia, extravillous trophoblast autophagy is impaired, as evidenced by reduced LC3B expression and stabilization or accumulation of p62 (20) , as has been observed in other systems (38, 39) . Consistent with this observation, we observed expression of the autophagy marker LC3B-II under resting conditions, but in the presence of aPL, LC3B-II expression was inhibited, and p62 levels were stabilized, indicating that autophagy was impaired.
Furthermore, inhibition of autophagy by bafilomycin induced a similar response to aPL, while maintenance of autophagy by rapamycin prevented aPL-induced inflammasome activity and subsequent IL-1b secretion. Mechanisms by which autophagy may prevent inflammasome activation include inhibiting production of reactive oxygen species (58), promoting inflammasome degradation (18) , or sequestering pro-IL-1b and targeting it for lysosomal degradation (58) . This latter mechanism is unlikely, because pro-IL-1b is highly expressed in untreated trophoblasts (9) . How the TLR-4-mediated uric acid response is regulated remains unclear, because it is modulated by neither the TAM receptor pathway nor autophagy.
In summary, our data showed that human extravillous trophoblast TLR and inflammasome function are tightly regulated by immunomodulatory pathways: TAM receptor activity and autophagy. Disabling of the TAM receptor signaling pathway by an anti-b 2 GPI antibody results in TLR-4 activation, leading to subsequent TLR-8-mediated IL-8 release. Impaired autophagy by this anti-b 2 GPI aPL allows inflammasome activity leading to IL-1b production. These advancements in our understanding of the mechanisms by which anti-b 2 GPI aPL might mediate placental inflammation may further the potential for new predictive markers and therapeutic targets for preventing obstetric antiphospholipid syndrome.
